KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to $136.1 million.

  • Eli Lilly's Share-based Compensation fell 435.7% to $136.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $626.0 million, marking a year-over-year decrease of 309.6%. This contributed to the annual value of $626.0 million for FY2025, which is 309.6% down from last year.
  • Eli Lilly's Share-based Compensation amounted to $136.1 million in Q4 2025, which was down 435.7% from $151.1 million recorded in Q3 2025.
  • In the past 5 years, Eli Lilly's Share-based Compensation registered a high of $215.6 million during Q3 2023, and its lowest value of $75.3 million during Q4 2021.
  • For the 5-year period, Eli Lilly's Share-based Compensation averaged around $130.7 million, with its median value being $132.2 million (2023).
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 15334.9% in 2023, then tumbled by 3821.89% in 2024.
  • Over the past 5 years, Eli Lilly's Share-based Compensation (Quarter) stood at $75.3 million in 2021, then rose by 23.37% to $92.9 million in 2022, then rose by 29.92% to $120.7 million in 2023, then grew by 17.9% to $142.3 million in 2024, then dropped by 4.36% to $136.1 million in 2025.
  • Its Share-based Compensation was $136.1 million in Q4 2025, compared to $151.1 million in Q3 2025 and $185.1 million in Q2 2025.